JP2021520368A5 - - Google Patents

Info

Publication number
JP2021520368A5
JP2021520368A5 JP2020554198A JP2020554198A JP2021520368A5 JP 2021520368 A5 JP2021520368 A5 JP 2021520368A5 JP 2020554198 A JP2020554198 A JP 2020554198A JP 2020554198 A JP2020554198 A JP 2020554198A JP 2021520368 A5 JP2021520368 A5 JP 2021520368A5
Authority
JP
Japan
Prior art keywords
individual
tumor
poliovirus
immune checkpoint
tumors
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2020554198A
Other languages
English (en)
Japanese (ja)
Other versions
JP2021520368A (ja
JP7550449B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2019/025402 external-priority patent/WO2019195302A1/en
Publication of JP2021520368A publication Critical patent/JP2021520368A/ja
Publication of JP2021520368A5 publication Critical patent/JP2021520368A5/ja
Application granted granted Critical
Publication of JP7550449B2 publication Critical patent/JP7550449B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2020554198A 2018-04-02 2019-04-02 ネオアジュバントがん治療 Active JP7550449B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201862651470P 2018-04-02 2018-04-02
US62/651,470 2018-04-02
US201962823277P 2019-03-25 2019-03-25
US62/823,277 2019-03-25
PCT/US2019/025402 WO2019195302A1 (en) 2018-04-02 2019-04-02 Neoadjuvant cancer treatment

Publications (3)

Publication Number Publication Date
JP2021520368A JP2021520368A (ja) 2021-08-19
JP2021520368A5 true JP2021520368A5 (enExample) 2022-04-12
JP7550449B2 JP7550449B2 (ja) 2024-09-13

Family

ID=68101391

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2020554198A Active JP7550449B2 (ja) 2018-04-02 2019-04-02 ネオアジュバントがん治療

Country Status (8)

Country Link
US (2) US20210106633A1 (enExample)
EP (1) EP3773650A4 (enExample)
JP (1) JP7550449B2 (enExample)
KR (1) KR20200139738A (enExample)
CN (2) CN112118853A (enExample)
AU (1) AU2019247039B2 (enExample)
CA (1) CA3095591A1 (enExample)
WO (1) WO2019195302A1 (enExample)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2018067446A1 (en) 2016-10-06 2018-04-12 Duke University Detection of cd-155, the poliovirus receptor
US11311628B2 (en) 2016-10-17 2022-04-26 Duke University Production of immunotoxin D2C7—(scdsFv)—PE38KDEL
US20220387529A1 (en) * 2019-11-04 2022-12-08 Duke University Treatment for primary and metastatic cancer
WO2023141229A2 (en) * 2022-01-19 2023-07-27 Istari Oncology, Inc. Oncolytic virus regimens for the treatment of cancer
WO2023141236A2 (en) * 2022-01-19 2023-07-27 Istari Oncology, Inc. Methods for treating bladder cancers by intravesical instillation of a chimeric poliovirus
CN114931637B (zh) * 2022-06-27 2025-02-18 中山大学中山眼科中心 Pdl1抗体在角膜新生血管疾病中的应用
WO2025019822A1 (en) * 2023-07-19 2025-01-23 Istari Oncology, Inc. Methods of treatment with a chimeric poliovirus in patients with glioblastoma

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2688653T3 (es) * 2012-11-21 2018-11-06 Duke University Poliovirus oncolítico para tumores humanos
US10744170B2 (en) * 2015-10-15 2020-08-18 Duke University Combination treatment
CN108135934B (zh) * 2015-10-19 2024-09-10 永恒生物科技股份有限公司 通过组合疗法治疗实体或淋巴肿瘤的方法
CN108367070B (zh) * 2015-11-04 2022-10-28 杜克大学 免疫毒素与检查点抑制剂的组合治疗
EP3389712B1 (en) * 2015-12-17 2024-04-10 Novartis AG Antibody molecules to pd-1 and uses thereof
ES3041500T3 (en) * 2016-03-10 2025-11-12 Cg Oncology Inc Methods of treating solid tumors by combination therapy
ES2891577T3 (es) * 2016-03-21 2022-01-28 Univ Duke Tratamiento contra el cáncer secuencial
US20190202886A1 (en) * 2016-05-11 2019-07-04 Ohio State Innovation Foundation ONCOLYTIC VIRUSES COMPRISING esRAGE AND METHODS OF TREATING CANCER
CN109789177A (zh) 2016-05-27 2019-05-21 德那翠丝有限公司 腺病毒和免疫调节剂组合治疗
US20220387529A1 (en) * 2019-11-04 2022-12-08 Duke University Treatment for primary and metastatic cancer

Similar Documents

Publication Publication Date Title
Ventola Cancer immunotherapy, part 2: efficacy, safety, and other clinical considerations
JP2023130496A (ja) 癌治療のための併用療法
JP4576005B2 (ja) 腫瘍および炎症性疾患を選択的に治療するために用いられる、壊死を引き起こす物質と、壊死により活性化される物質との組み合わせ
EP3581182B1 (en) Combination treating prostate cancer, pharmaceutical composition and treatment method
TWI818120B (zh) 藉由免疫檢查點阻礙藥與ｆｏｌｆｉｒｉｎｏｘ療法之併用的癌症治療
JP2020500181A5 (enExample)
FI3728313T3 (fi) Syövän yhdistelmähoito IAP-antagonistilla ja anti-PD-1-molekyylillä
WO2013189516A1 (en) Method for treating a gd2 positive cancer
US20250241969A1 (en) Neoadjuvant cancer treatment
CN109475576A (zh) 用于治疗her2阳性转移性乳腺癌的组合物和方法
JP2020183447A5 (enExample)
Gervaso et al. Immunotherapy in the neoadjuvant treatment of gastrointestinal tumors: is the time ripe?
EP2710038B1 (en) COMBINATIONS OF ANTI ErbB ANTIBODIES FOR THE TREATMENT OF CANCER
JP2023505222A5 (enExample)
WO2017120997A1 (zh) 共表达抗EGFRvIII嵌合抗原受体和无功能EGFR的转基因淋巴细胞及其用途
Serre et al. Brachytherapy: perspectives for combined treatments with immunotherapy
CN111867598A (zh) 肿瘤免疫赋活剂
WO2023272831A1 (zh) 水苏糖在制备用于治疗去势抵抗性前列腺癌药物中的应用
BR112020025203A2 (pt) Materiais e métodos para tratar distúrbios relacionados o estresse e câncer
US20220265716A1 (en) Antibody pre-loaded cd16+nk-92 cells as an effective therapeutic product for tumor lysis
Arabpour et al. Cancer immunotherapy
CN106963950B (zh) 用于治疗肿瘤的联合用药物
WO2009147695A1 (ja) 抗がん剤
EP4681707A1 (en) Method for treating diseases by using reparixin alone or in combination with anti-pd-1 antibody
Chaturvedi et al. Immunotherapy for breast cancer